Physician
Kumar, Ratnesh
Kumar, Ratnesh was paid $1.63M by Medicaid between Jun 2018 and Dec 2024, across 31 billing codes. Its largest line is 87633, Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets — 55% of everything it billed.
33Billing provider infoKUMAR, RATNESH
HOFFMAN ESTATES, IL 60169
HOFFMAN ESTATES, IL 60169
33aNPI1952544918assigned 04/07/2009
33bProvider typePediatrics Physician
28Total paid$1.63M
24GClaims20,564
24DCodes billed31
24AFirst – last monthJun 2018 – Dec 2024
Compared with peers
Next to other Pediatrics Physician providers in Illinois
Rank by total paid#60 of 1,805
Median peer was paid$55K
This provider vs. median30×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 154 | $5K | |
| 2019 | 450 | $22K | |
| 2020 | 54 | $3K | |
| 2022 | 3,400 | $228K | |
| 2023 | 5,031 | $271K | |
| 2024incomplete | 11,475 | $1.10M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 55% | 2,648 | 2,282 | $904K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 15% | 4,889 | 4,190 | $250K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 11% | 3,766 | 3,421 | $186K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 4.0% | 4,234 | 3,665 | $65K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 3.9% | 949 | 744 | $64K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 3.8% | 679 | 614 | $63K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 1.3% | 231 | 212 | $21K |
| 87486 | <1% | 331 | 291 | $15K | |
| 87581 | <1% | 331 | 291 | $15K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 323 | 293 | $11K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 393 | 353 | $9K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 29 | 22 | $7K |
19 more codes
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 563 | $5K |
| 99000 | <1% | 200 | $5K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 16 | $2K |
| 94762 | <1% | 73 | $2K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 16 | $1K |
| 87400 | <1% | 89 | $722.85 | |
| 81003 | <1% | 306 | $655.09 | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 22 | $430.89 |
| 87081 | <1% | 73 | $411.80 | |
| 94760 | <1% | 132 | $402.86 | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 13 | $330.65 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 13 | $325.00 |
| 96127 | <1% | 41 | $248.48 | |
| 81025 | <1% | 48 | $243.00 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 16 | $232.00 |
| 92587 | <1% | 18 | $210.29 | |
| 81002 | <1% | 62 | $156.68 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 32 | $19.53 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 28 | $19.31 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.